ERBB2 and breast cancer: Specifically, we observed that aggressive non-luminal cancers (HER2 positive and TN) presented with significantly lower MRO2 (i.e., metabolic rate of oxygen) than less aggressive luminal cancers (luminal A and luminal B) and lower mitoPO2 values (i.e., hypoxia) than luminal breast cancers.